BIOATLA, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
BIOATLA, INC. (BCAB) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $3.09 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-13
- BIOATLA, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $18.00K, a 95.72% decline year-over-year.
- BIOATLA, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $3.07M, a 45.18% increase year-over-year.
- BIOATLA, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$747.00K.
- BIOATLA, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $1.02M, a 58.75% increase year-over-year.
- BIOATLA, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $2.80M.
- BIOATLA, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was -$13.46M, a 354.75% decline from fiscal 2023.
- BIOATLA, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $5.28M, a 54.91% increase from fiscal 2022.
- BIOATLA, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $3.41M, a 57.32% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $3.09M 10-Q · filed 2026-08-13 | $2.34M derived: sum of 3 quarters · filed 2026-08-13 | $3.36M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $3.07M 10-Q · filed 2026-05-15 | $2.32M derived: sum of 2 quarters · filed 2026-05-15 | $3.34M derived: sum of 3 quarters · filed 2026-05-15 | $3.76M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$747.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $269.00K derived: sum of 2 quarters · filed 2026-03-31 | $690.00K derived: sum of 3 quarters · filed 2026-08-13 | $2.80M 10-K · filed 2026-03-31 |
| 2025-09-30 | $1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.44M derived: sum of 2 quarters · filed 2026-08-13 | $3.55M 10-Q · filed 2025-11-13 | $374.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $421.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $2.54M 10-Q · filed 2026-08-13 | -$642.00K derived: sum of 3 quarters · filed 2026-08-13 | -$2.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $2.11M 10-Q · filed 2026-05-15 | -$1.06M derived: sum of 2 quarters · filed 2026-05-15 | -$423.00K derived: sum of 3 quarters · filed 2026-05-15 | -$2.37M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$3.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$2.54M derived: sum of 2 quarters · filed 2026-03-31 | -$4.48M derived: sum of 3 quarters · filed 2026-03-31 | -$13.46M 10-K · filed 2026-03-31 |
| 2024-09-30 | $640.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$1.31M derived: sum of 2 quarters · filed 2025-11-13 | -$10.28M 10-Q · filed 2025-11-13 | -$17.53M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$1.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$10.92M 10-Q · filed 2025-08-07 | -$18.17M derived: sum of 3 quarters · filed 2025-08-07 | -$16.21M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$8.98M 10-Q · filed 2025-05-06 | -$16.23M derived: sum of 2 quarters · filed 2025-05-06 | -$14.27M derived: sum of 3 quarters · filed 2025-05-06 | -$6.84M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$7.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$5.29M derived: sum of 2 quarters · filed 2025-03-28 | $2.13M derived: sum of 3 quarters · filed 2025-03-28 | $5.28M 10-K · filed 2025-03-28 |
| 2023-09-30 | $1.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $9.38M derived: sum of 2 quarters · filed 2024-11-07 | $12.53M 10-Q · filed 2024-11-07 | $11.80M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $7.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $10.57M 10-Q · filed 2024-08-08 | $9.84M derived: sum of 3 quarters · filed 2024-08-08 | $8.14M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $3.15M 10-Q · filed 2024-05-14 | $2.42M derived: sum of 2 quarters · filed 2024-05-14 | $713.00K derived: sum of 3 quarters · filed 2024-05-14 | $8.99M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$735.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$2.44M derived: sum of 2 quarters · filed 2024-03-26 | $5.84M derived: sum of 3 quarters · filed 2024-03-26 | $3.41M 10-K · filed 2024-03-26 |
| 2022-09-30 | -$1.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $6.58M derived: sum of 2 quarters · filed 2023-11-07 | $4.15M 10-Q · filed 2023-11-07 | $1.29M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $8.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $5.85M 10-Q · filed 2023-08-01 | $3.00M derived: sum of 3 quarters · filed 2023-08-01 | $8.13M derived: sum of 4 quarters · filed 2023-08-01 |
| 2022-03-31 | -$2.43M 10-Q · filed 2023-05-11 | -$5.29M derived: sum of 2 quarters · filed 2023-05-11 | -$157.00K derived: sum of 3 quarters · filed 2023-05-11 | $5.44M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$2.85M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $2.28M derived: sum of 2 quarters · filed 2023-03-23 | $7.88M derived: sum of 3 quarters · filed 2023-03-23 | $7.99M 10-K · filed 2023-03-23 |
| 2021-09-30 | $5.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $10.73M derived: sum of 2 quarters · filed 2022-11-04 | $10.84M 10-Q · filed 2022-11-04 | $7.88M derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $5.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $5.72M 10-Q · filed 2022-08-09 | $2.75M derived: sum of 3 quarters · filed 2022-08-09 | -$1.81M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $117.00K 10-Q · filed 2022-05-05 | -$2.85M derived: sum of 2 quarters · filed 2022-05-05 | -$7.41M derived: sum of 3 quarters · filed 2022-05-05 | -$4.02M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | -$2.97M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$7.53M derived: sum of 2 quarters · filed 2022-02-28 | -$4.14M derived: sum of 3 quarters · filed 2022-02-28 | -$1.66M 10-K · filed 2022-02-28 |
| 2020-09-30 | -$4.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$1.17M derived: sum of 2 quarters · filed 2021-11-15 | $1.31M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $3.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $5.87M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $2.48M 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $3.22M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |